DAFNA Capital Management’s UroGen Pharma URGN Stock Holding History

DAFNA Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,515	Closed	-$549K	–	87
2025 Q3	$549K	Sell	27,515 -322,000	-92%	-$5.78M	0.14%	67
2025 Q2	$4.79M	Sell	349,515 -143,000	-29%	-$1.37M	1.32%	23
2025 Q1	$5.45M	Hold	492,515	–	–	1.54%	18
2024 Q4	$5.25M	Buy	492,515 +33,600	+7%	+$402K	1.33%	19
2024 Q3	$5.83M	Sell	458,915 -10,085	-2%	-$150K	1.38%	22
2024 Q2	$7.87M	Buy	+469,000	New	+$6.67M	1.88%	20
2020 Q2	–	Sell	-2,369	Closed	-$42K	–	92
2020 Q1	$42K	Sell	2,369 -1,618	-41%	-$43.7K	0.02%	80
2019 Q4	$133K	Sell	3,987 -11,013	-73%	-$301K	0.05%	79
2019 Q3	$357K	Hold	15,000	–	–	0.13%	77
2019 Q2	$539K	Hold	15,000	–	–	0.2%	69
2019 Q1	$554K	Hold	15,000	–	–	0.24%	65
2018 Q4	$646K	Hold	15,000	–	–	0.32%	55
2018 Q3	$708K	Buy	15,000 +5,000	+50%	+$232K	0.29%	57
2018 Q2	$498K	Buy	10,000 +5,500	+122%	+$320K	0.23%	61
2018 Q1	$224K	Buy	+4,500	New	+$225K	0.11%	68

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

DAFNA Capital Management's URGN Position: Q4 2025 in Review

DAFNA Capital Management sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 27,515 shares — an estimated $549K sold.

DAFNA Capital Management first reported a position in URGN in Q1 2018 and held it in 15 quarters. The position peaked at $7.87M in Q2 2024. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

DAFNA Capital Management reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
DAFNA Capital Management sold 27,515 UroGen Pharma shares in Q4 2025, an estimated $549K.
DAFNA Capital Management first reported a position in UroGen Pharma in Q1 2018 and held it in 15 quarters.
DAFNA Capital Management's UroGen Pharma position peaked at $7.87M in Q2 2024.
167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.